# LAZCLUZE

NDC: 57894-240
Generic name: lazertinib
Labeler / Manufacturer: Janssen Biotech, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: TABLET, FILM COATED
Routes: ORAL
Marketing started: 20240820

FDA application: NDA219008

## Active ingredients

- LAZERTINIB: 240 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"57894-240"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=57894-240
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c417f9ee-2027-4ed5-92ad-3c19266de16c